Second-line and beyond in mCRC: Optimising the benefit and reducing the risk
9 May 2019
Second-line and beyond in mCRC: Optimising the benefit and reducing the risk
Controversies in the management of prostate cancer
Highlights from IGILUC 2019
Advanced gastric cancer: What do we know and what we must know?
How the WIN consortium achieves its goals
The translational element of the WIN consortium
Making oncology global with the WIN consortium
An overview of the WIN consortium
The WIN symposium 2019
5' UTR mutations in prostate cancer
The hereditary link between African-Americans and people in Africa and its relationship to cancer incidence and outcomes
Risk factors for prostate cancer in men of African descent